https://www.selleckchem.com/products/h-151.html
Survival outcomes (progression- free survival [PFS] and overall survival [OS]) were analyzed. Results Among the 49 patients who showed a clinical benefit during cisplatin- doublet therapy, 24 were maintained on the doublet regimen, 16 were switched to single-maintenance treatment, and chemotherapy was suspended until disease progression in nine patients. The single-maintenance chemotherapy group showed superior survival than the chemotherapy holiday and doublet regimen groups (median PFS 15.43 months vs. 8.37 and 10.67 months, respectivel
Like
Comment
Share
